Protein Crystallization Imager

项目总结 此应用程序正在申请资金，以购买Formulatrix Rock Imager®2，具有双光路和 能够同时进行紫外线(UV)和多荧光成像，以监控和捕获高通量 结晶筛选实验。新成像器的主要应用将是加速 用于大分子X射线的机构先进技术核心(ATC)中的结晶筛选 贝勒医学院(BCM)的结晶学。岩石成像仪2将取代现有的成像设备 2008年购买的系统，将不再由制造商进行维护或维修。新的 成像仪将增强X射线核心的能力，使蛋白质晶体和 荧光标记大分子络合物的晶体。除了七个主要用户外，他们还 在蛋白质结晶或使用X射线结晶学进行研究方面经验丰富，有四个较小的使用者 表示有兴趣使用岩石成像仪2通过大分子X射线进行结晶筛选 结晶学ATC 除了BCM，德克萨斯医学中心(TMC)只有另外两个学术机构 拥有成像系统，这两个系统都不能供核心员工使用。所请求的仪器将 由X-射线核心负责托管和管理，为蛋白质的结晶提供主要服务 与核酸、小分子或两者兼而有之的功能配合物。不断增长的发现新药的需求 反映了学院在精准医学和转化研究方面的战略计划，其中卫生 专业人士和基础研究人员共同开发针对新出现的感染的新疗法 疾病、糖尿病和肥胖症、男性避孕药、癌症和阿尔茨海默病。除了大量的 增强核心的工作流程，新的成像器将推进用户的个人研究计划，并将 提供给TMC的所有研究人员，以帮助找到他们的大分子的结构溶液 利息。

PROJECT SUMMARY This application is requesting funds to purchase a Formulatrix ROCK IMAGER® 2 with Dual Light Path and capable of both ultraviolet (UV) and multi-fluorescence imaging to monitor and capture high-throughput crystallization screening experiments. The primary application of the new imager will be to accelerate crystallization screening in the institutional Advanced Technology Core (ATC) for Macromolecular X-ray Crystallography at Baylor College of Medicine (BCM). The ROCK IMAGER 2 will replace the existing imaging system that was purchased in 2008, and will be no longer maintained or serviced by the manufacturer. The new imager will enhance the capabilities of the X-ray Core by enabling the rapid screening of protein crystals and crystals of fluorescently-labeled macromolecular complexes. In addition to the seven Major Users, who are experienced with protein crystallization or use X-ray crystallography for their research, four Minor Users have expressed interest in using the ROCK IMAGER 2 for crystallization screening through the Macromolecular X-ray Crystallography ATC. Besides BCM, there are only two other academic institutions in the Texas Medical Center (TMC) possessing an imaging system, neither of which is available for use by Core Staff. The requested instrument will be housed and managed by the X-ray Core to provide major services for the crystallization of proteins and their functional complexes with nucleic acids, small molecules, or both. The growing demand to discover new drugs reflects the College’s strategic plans for precision medicine and translational research, where health professionals and basic researchers come together to develop new therapeutics against emerging infectious diseases, diabetes and obesity, male contraceptive, cancer, and Alzheimer's disease. In addition to greatly enhancing the Core's workflow, the new imager will advance the individual research programs of users and will be made available to all investigators in the TMC to help find a structure solution of their macromolecule of interest.